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Abstract: Background: Migrant women are one of the most vulnerable population to health problems
and well-being. This study aimed at implementing a counseling and preventive strategy for sexually
transmitted infections (STIs) in undocumented migrant women in Milan, Italy. Methods: Women
(ages 18–65) were enrolled at the NAGA Centre (2012–2013) and asked for a urine sample in
order to carry out molecular detection of Human papillomavirus (HPV), Chlamydia trachomatis
(Ct), Trichomonas vaginalis (Tv), Neisseria gonorrhoeae (Ng)-DNA. Socio-demographic and sexual
behavior information were collected. All HPV/Ct+ women were offered Pap tests and/or were
prescribed antibiotic treatment. Results: 537/757 women participated in the study (acceptability rate:
70.9%). Most of the women were from Latin America (45.6%) and Eastern Europe (30.7%); >60%
of them had stable partners, did not use contraception and had had at least one pregnancy. The
prevalence rates of HPV, Ct, Tv and Ng infections were 24.2%, 7.8%, 4.8% and 0%, respectively. In all,
43.2% of the positive women agreed to undergo a gynecological examination and accepted suitable
treatment. Conclusions: This study shows an overall high prevalence of STIs in undocumented
migrant women in Milan. The screening strategy based on counseling and urine testing contributed
to the successfully high acceptability rate. More appropriate health services that adequately address
all aspects of women’s health are required.
Keywords: undocumented migrant women; sexual health; sexually transmitted infections;
prevalence; STI screening
1. Introduction
We are living in the era of the greatest human mobility ever recorded in history. According
to the United Nations Secretariat [1], the number of international migrants is estimated at
244 million, representing approximately 3.3% of the world population. Although they are harder to
quantify, undocumented migrants are estimated to be 15–30 million worldwide (International Labor
Organization, ILO) [2]. In Italy, there were 5 million migrants in 2012, and approximately 23.7% of
them were living in the Lombardy Region [3].
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Nearly half of all international migrants are women and girls, more and more of whom are
migrating independently of the male population [4]. Therefore, migration is a factor to be considered
in issues related to women, as it may lead to the worsening or improvement of women’s health.
The conditions of migration, the extent of integration into the host society, the social status of the
woman and the health regulations in force in the host country are all factors that affect the well-being of
women. Women who migrate from low-income to high-income countries [5] are more likely to benefit
from the host country’s health system, provided that they can speak the language of the host country
and are employed. However, women are usually completely dependent on their husbands/partners
and may not be able to access the health system to obtain adequate information and health care due
to lack of health insurance and problems of male dominance [6]. In fact, migrants often move with
their culture and traditional norms and this is a particular challenge for women. For example, cultural
norms may prevent women from accepting care from male practitioners. Moreover, educational
levels, misconceptions and prejudices hinder their access to and the success of health prevention
programs. In addition, the lack of language skills can be a major barrier to understanding health care
procedures and the functioning of the health system [7–10]. Therefore, in order to improve the welfare
of the female migrant population, an appropriate education related to all aspects of women’s health is
required, particularly in the field of reproductive and sexual health.
Sexually transmitted infections (STIs) are one of the main public health problems affecting migrant
women [11]. Most STIs are asymptomatic, but they can cause acute illnesses, chronic infections and
serious delayed sequelae, such as infertility, ectopic pregnancies, cancer, long-term disability and
premature deaths. Undocumented migrants are often denied access to public health services or
are reluctant to use services that are available for them for fear of being deported. Even migrants
who are legally entitled to health care may face various obstacles to utilizing these services [9,10].
In Italy, very few data are available regarding STI surveillance among migrant women, especially
undocumented women [12–14]. Furthermore, although under Italian law health care is available
to all migrants, including illegal migrants, no national preventive action targeted at the sexual
health of female migrants has been implemented. Consequently, their access to screening is almost
inexistent and the admission to medical care is limited to emergencies, when the disease has become
symptomatic. In order to overcome these problems and to gain insight on sexual health in migrant
women, we implemented a counseling and a preventive strategy for controlling STIs in undocumented
migrant women (i.e., foreign-born person not having the official documents that are needed to enter,
live in, or work in a country legally), in Milan. Urine sampling, which is non-invasive and easy
to collect, was selected in order to avoid gynaecological examinations that may run counter to
socio-cultural and religious beliefs, as well as to improve screening coverage.
In particular, we focused on two of the most common STIs worldwide [11], Human papillomavirus
(HPV) and Chlamydia trachomatis (Ct) infections. As a secondary aim, we performed a pilot study to
investigate the spread of another two STI infections, Neisseria gonorrhoeae (Ng) and Trichomonas vaginalis
(Tv) in the same population.
2. Results
2.1. Study Population and Acceptability to the Study
From June 2012 to December 2013, 757 undocumented migrant women attending the NAGA
Centre in Milan (Italy) [15], were invited to take part in the study, regardless of the reason (medical
or otherwise) for their visit to the Centre. Informed consent, a questionnaire regarding their
socio-demographic profile and sexual and reproductive health behaviour, as well as a first void
urine sample were obtained from each participant. Overall, 537 women, aged 18–65 years, agreed
to participate in the study. Therefore, the acceptability rate was 70.9% (95% Confidence Interval,
95% CI 67.7–74.1). Lack of time was the main reason that women (198/757; 26%) gave for refusing
to participate. Twenty-two women refused to complete the questionnaire and give informed consent
Int. J. Mol. Sci. 2017, 18, 1311 3 of 13
to the study due to the prevailing decisions of husbands/partners. This reason could have created a
potential selection bias, but the proportion (22/757; 2.9%) was very low.
2.2. Socio-Demographic and Sexual Health Characteristics
The 537 women enrolled had a median age of 36 years (InterQuartile Range, IQR: 28–47).
Subdividing for age-classes, 15.4% (n = 83) of women aged <25 years, 30% (n = 161) 25–34 years,
24.4% (n = 131) 35–44 years, 19.2% (n = 103) 45–54 years, and 11% (n = 59) ≥ 55 years. Regarding
geographical origin, the women came from 39 different countries belonging to six World Health
Organization (WHO) Regions: 45.6% (n = 245) of them were from Latin America [in particular, 38%
from Peru, 20% from El Salvador, 17% from Ecuador, 9% from Brazil and 8% from Bolivia]; 30.7%
(n = 165) came from Eastern Europe (47% from Romania, 22% from Ukraine, 11.5% from Albania,
9% from Moldova, 8% from Bulgaria, 2.5% from Kazakhstan, Serbia and the Russian Federation).
The remaining 23.7% were from Eastern Mediterranean countries (8% (n = 43), for the most part from
Morocco (67%)); Western Pacific (6.7% (n = 36), for the most part from Philippines (72%)), Africa (6.3%
(n = 34), 32% of whom from Nigeria), and; Southeast Asia (2.6% (n = 14), all from Sri Lanka).
Table 1 summarizes the socio-demographic and sexual-reproductive health characteristics of the
women included in the study.
Table 1. Socio-demographic and sexual health characteristics of 537 women enrolled: overall and by
geographical World Health Organization (WHO) Region.
Characteristics of
Enrolled Women
Overall LatinAmerica
Eastern
Europe
Eastern
Mediterranean
Western
Pacific Africa
Southeast
Asia
n % n % n % n % n % n % n %
537 100 245 45.6 165 30.7 43 8.0 36 6.7 34 6.3 14 2.6
Socio-demographic characteristics
Migration time *
≤1 year 121 22.5 61 24.9 29 17.6 9 20.9 10 27.8 9 26.5 3 21.4
2–3 years 112 20.9 55 22.4 27 16.4 10 23.3 10 27.8 7 20.6 3 21.4
4–5 years 55 10.2 23 9.4 18 10.9 7 16.3 3 8.3 3 8.8 1 7.2
>5 years 249 46.4 106 43.3 91 55.1 17 39.5 13 36.1 15 44.1 7 50.0
Marital status
Single or widow 134 24.9 63 25.7 36 21.8 14 32.5 5 13.9 16 47.1 0 0.0
Married 308 57.4 138 56.3 95 57.6 18 41.9 27 75.0 17 50.0 13 92.9
Divorced or
separated 95 17.7 44 18.0 34 20.6 11 25.6 4 11.1 1 2.9 1 7.1
Educational background
No qualification 29 5.4 2 0.8 20 12.1 5 11.6 0 0.0 3 8.8 0 0.0
Elementary school 83 15.4 31 12.7 24 14.6 11 25.5 5 13.9 6 17.6 5 35.7
Secondary school 47 8.8 24 9.8 14 8.5 6 14.0 1 2.8 1 3.0 1 7.2
High school 307 57.2 154 62.8 70 42.4 15 34.9 18 50.0 18 53.0 8 57.1
Degree 71 13.2 34 13.9 37 22.4 6 14.0 12 33.3 6 17.6 0 0.0
Sexual and reproductive health characteristics
Age at first intercourse
Virgins 7 1.3 0 0.0 3 1.8 3 7.0 0 0.0 1 3.0 0 0.0
≤15 years 94 17.5 47 19.2 28 17.0 6 14.0 1 2.8 6 17.6 6 42.9
16–19 years 238 44.3 117 47.8 83 50.3 13 30.2 14 38.9 10 29.4 1 7.1
>19 years 190 35.4 78 31.8 49 29.7 18 41.8 21 58.3 17 50.0 7 50.0
Don’t remember 8 1.5 3 1.2 2 1.2 3 7.0 0 0.0 0 0.0 0 0.0
Sexual activity
No partner 138 25.7 65 26.5 41 24.8 10 23.2 6 16.7 13 38.2 3 21.5
Stable partner
(>1 year) ** 350 65.2 156 63.7 111 67.3 27 62.8 30 83.3 17 50.0 9 64.3
Recently partner
(<1 year) 47 8.7 24 9.8 12 7.3 6 14.0 0 0.0 4 11.8 1 7.1
More partners 2 0.4 0 0.0 1 0.6 0 0.0 0 0.0 0 0.0 1 7.1
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Table 1. Cont.
Characteristics of
Enrolled Women
Overall LatinAmerica
Eastern
Europe
Eastern
Mediterranean
Western
Pacific Africa
Southeast
Asia
n % n % n % n % n % n % n %
537 100 245 45.6 165 30.7 43 8.0 36 6.7 34 6.3 14 2.6
Contraceptive methods
None 348 64.8 143 58.3 119 72.1 27 62.8 27 75.0 20 58.8 12 85.8
Condom 45 8.4 24 9.8 11 6.7 0 0.0 2 5.6 7 20.6 1 7.1
Pill 107 19.9 58 23.7 21 12.7 14 32.6 6 16.7 7 20.6 1 7.1
Others 37 6.9 20 8.2 14 8.5 2 4.6 1 2.7 0 0.0 0 0.0
Pregnancies
None 161 30.0 78 31.8 38 23.0 20 46.5 4 11.1 18 52.9 3 21.5
1 140 26.1 61 24.9 44 26.7 10 23.2 13 36.1 7 20.6 5 35.7
2 121 22.5 48 19.6 48 29.1 9 20.9 12 33.3 2 5.9 2 14.2
3 70 13.0 33 13.5 23 13.9 2 4.7 5 13.9 3 8.8 4 28.6
>3 45 8.4 25 10.2 12 7.3 2 4.7 2 5.6 4 11.8 0 0.0
Past Sexually Transmitted Diseases (STD symptomatic cases)
Yes 142 26.4 74 30.2 48 29.1 9 20.9 2 5.6 9 26.5 0 0.0
Type of STDs
Condyloma 5 0.9 3 1.2 2 1.2 0 0.0 0 0.0 0 0.0 0 0.0
Syphilis 1 0.2 1 0.4 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Gonorrhoea 1 0.2 1 0.4 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Chlamydia 3 0.6 1 0.4 2 1.2 0 0.0 0 0.0 0 0.0 0 0.0
Genital Herpes 4 0.7 3 1.2 1 0.6 0 0.0 0 0.0 0 0.0 0 0.0
Bacterial vaginosis 37 6.9 20 8.2 10 6.1 1 2.3 1 2.8 5 14.8 0 0.0
Mycosis 36 6.7 17 6.9 14 8.5 4 9.3 0 0.0 1 2.9 0 0.0
Trichomoniasis 1 0.2 0 0.0 0 0.0 1 2.3 0 0.0 0 0.0 0 0.0
Bacterial
vaginosis/mycosis 21 3.9 10 4.2 8 4.8 2 4.7 0 0.0 1 2.9 0 0.0
Others 33 6.1 18 7.3 11 6.7 1 2.3 1 2.8 2 5.9 0 0.0
* Migration time: time of residence in Italy; ** Stable partner (>1 year): same sex partner for at least one year.
Sexually transmitted infection (STI).
A total of 46.4% of the undocumented women had been living in Italy for more than 5 years,
57.4% were married or had stable partners, and 70.4% had a high level of education (high school
or degree). As for the risk factors associated with sexual health, 44.3% of women first had sexual
intercourse between 16 and 19 years of age. As regards to geographical origin, women from the Eastern
Mediterranean, Western Pacific, Africa and Southeast Asia first had sexual intercourse later in life
(>19 years, p = 0.05). 65.2% of women reported to have stable sexual partners and 64.8% did not use
contraceptive methods. Seventy percent of the women had had at least one pregnancy, 26.4% reported
to have had any Sexually Transmitted Disease (STD) in the past. Specifically, 6.7% reported mycosis
and 6.9% reported bacterial vaginosis.
2.3. Evaluation of DNA Quality
The β-globin gene was amplified from all 537 urine samples collected, thus confirming the
suitability of the extraction protocol.
2.4. HPV Detection and Genotyping
Overall, the prevalence of HPV infection was 24.2% (95% CI: 20.7–28; 130/537). By subdividing
for geographical origin, the percentages of HPV DNA positive women were: 29.4% (95% CI: 24.1–35.6;
72/245) for those from Latin America, 27.8% (95% CI: 15–44; 10/36) from Western Pacific, 21.4% (95% CI:
5.8–47.9; 3/14) from Southeast Asia, 21% (95% CI: 10.2–33.5; 9/43) from the Eastern Mediterranean,
18.2% (95% CI: 12.8–24.6; 30/165) from Eastern Europe, and 17.6% (95% CI: 7.5–33.1; 6/34) from
Africa. Comparisons of HPV DNA positivity among the geographical groups showed a statistically
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significant difference for women from Latin America versus those from Eastern Europe (29.4% vs.
18.2%, p = 0.009).
The median age of HPV DNA positive women was 37 years (IQR: 28–47). The age-stratified HPV
prevalence showed a peak among women <25 years (32.5%; 95% CI: 23.4–43.2; 27/83) while it was
constantly lower in the other age groups (21.7%, 26%, 21.3%, and 20.3% in women aged 25–34, 35–44,
45–54 and ≥55 years, respectively).
No meaningful comparison can be made regarding the prevalence of HPV infection by age and
geographical origin, since the women under analysis were randomly recruited (Table 2).
Table 2. Age-stratified Human papillomavirus (HPV) prevalence of 537 women enrolled: overall and
by geographical WHO Region.
Age-Stratified
HPV Prevalence
Overall Latin America EasternEurope
Eastern
Mediterranean
Western
Pacific Africa
Southeast
Asia
n % n % n % n % n % n % n %
<25 years 27/83 32.5 17/42 40.5 9/32 28.1 1/7 14.3 0/0 0 0/2 0 0/0 0
25–34 years 35/161 21.7 20/75 26.7 7/48 14.6 3/15 20 2/4 50 3/15 20 0/4 0
35–44 years 34/131 26 16/60 26.7 5/32 15.6 2/12 16.7 5/12 41.7 3/11 27.3 3/4 75
45–54 years 22/103 21.3 11/44 25 6/32 18.7 2/8 25 3/13 23.1 0/2 0 0/4 0
>55 years 12/59 20.3 8/24 33.5 3/21 14.3 1/1 100 0/7 0 0/4 0 0/2 0
TOT 130/537 24.2 72/245 29.4 30/165 18.2 9/43 21 10/36 27.8 6/34 17.6 3/14 21.4
Overall, 77.7% (101/130) of HPV DNA positive samples were suitable (strong polymerase chain
reaction (PCR) signal) for Restriction Fragment Length Polymorphism (RFLP) typing. A total of 34
different HPV types were identified from the urine samples, 18 belonging to the High Risk-clade
(HR-clade: 52.9%) and 16 being Low Risk (LR) types (47.1%). Among typed infections, 85.2% (86/101)
were caused by a single HPV type, while 14.8% (15/101) were multiple infections. On the whole, 67.3%
(68/101) of infections were sustained by at least one type belonging to Group 1, which includes types
classified as being carcinogenic for humans [16].
Among the 508 women enrolled (excluding 29 women with untyped HPV DNA), HPV-56 was the
most frequent type in Group 1, with a frequency of 2.0% (10/508), followed by HPV-16 and HPV-52
(7/508, 1.4% each). HPV-18 was only detected in 0.2% (1/508) of the women enrolled (Figure 1).
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Figure 1. Distribution of HPV types among women (n = 508, excluding 29 women with untyped
HPV DNA). LA, Latin America; EE, Eastern Europe, EMed, Eastern Mediterranean; WP, Western
Pacific; A, Africa and SeA, Southeast Asia. According to the IARC classification system [16]:
Group 1 = carcinogenic to humans; Group 2A (HPV-68) = probably carcinogenic to humans; Group
2B = possibly carcinogenic to humans; Group 3 = not classifiable as carcinogenic to humans.
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2.5. C. trachomatis Detection and Genotyping
Overall, the prevalence of Ct infection was 7.8% (95% CI: 5.8–10.3; 42/537). Among the infected
women, 16.3% (95% CI: 7.4–29.6; 7/43) were from the Eastern Mediterranean region, 9.8% (95% CI:
6.5–14; 24/245) from Latin America, 8.8% (95% CI: 2.3–22.2; 3/34) from Africa, 5.6% (95% CI:
0.9–17.2; 2/36) from Western Pacific, and 3.6% (95% CI: 1.5–7.4; 6/165) from Europe. Comparisons
of geographical groups showed higher percentages of Ct DNA positivity among women from the
Eastern Mediterranean and Latin America versus European women (16.3% vs. 3.6% and 9.8% vs. 3.6%,
p = 0.007 and p = 0.01, respectively).
The median age of positive women was 28.5 years (IQR: 24.2–36). The prevalence peak was
observed in women <25 years (13.2%, 95% CI: 7.2–21.9) with a decrease according to age (11.2%, 4.6%,
3.9%, and 5% among women aged 25–34, 35–44, 45–54 and ≥55 years, respectively).
For the same reason mentioned above, no meaningful comparisons can be made regarding the
prevalence of Ct infection by age and geographical origin (Table 3).
Table 3. Age-stratified C. trachomatis prevalence of 537 women enrolled: overall and by geographical
WHO Region.
Age-Stratified Ct
Prevalence
Overall Latin America EasternEurope
Eastern
Mediterranean
Western
Pacific Africa
Southeast
Asia
n % n % n % n % n % n % n %
<25 years 11/83 13.2 10/42 23.8 0/32 0 1/7 14.3 0/0 0 0/2 0 0/0 0
25–34 years 18/161 11.2 8/75 10.7 2/48 4.2 5/15 33.4 1/4 25 2/15 13.4 0/4 0
35–44 years 6/131 4.6 2/60 3.3 2/32 6.2 1/12 8.3 0/12 0 1/11 9.1 0/4 0
45–54 years 4/103 3.9 3/44 6.8 0/32 0 0/8 0 1/13 7.7 0/2 0 0/4 0
>55 years 3/59 5 1/24 4.2 2/21 9.5 0/1 0 0/7 0 0/4 0 0/2 0
TOT 42/537 7.8 24/245 9.8 6/165 3.6 7/43 16.3 2/36 5.6 3/34 8.8 0/14 0
Fifty percent (21/42) of Ct DNA positive samples were successfully genotyped. Seven different
genovars, belonging to biovar trachoma, were identified: genovar E was the most frequently found
infecting seven samples (33.3%), followed by genovar G (19%, four samples), by genovar D and F (14.3%,
three samples each), H (9.5%, two samples), Ia and Ja (4.8%, one sample each).
2.6. HPV/C. Trachomatis Co-Infections
Among the 537 undocumented migrant women, 17 (3.2%; 95% CI: 1.9–5) were HPV/Ct co-infected.
There were no specific socio-demographic or sexual/reproductive health characteristics, or features of
the infecting pathogen, associated with co-infection.
2.7. Diagnostic and Therapeutic Follow-Up
All of the 155 HPV- and/or Ct-infected women were contacted by phone in order to inform
them of their STI status and to make a medical appointment. Overall, 28 (18.1%) women did not
answer the phone despite repeated attempts, 60 (38.7%) did not attend the medical appointment
for work, logistical, and/or personal reasons, and 67 (43.2%) agreed to undergo a gynaecological
examination and to have suitable treatment. The outcome of the Pap test carried out on 58 HPV DNA
positive women was: negative cytology in 77.6% (45/58) and atypical squamous cells of undetermined
significance (ASC-us) in 32.4% (13/58). Six women (6/13; 46.2%) with ASC-us were infected with HPV
types belonging to the HR-clade (HPV-16, -26, -51, -56, -66 and -82, respectively) and 7 (53.8%) were
infected with LR HPV types. Nine Ct infected women received specific antibiotic treatment.
The flowchart with the design of the study and the main results is reported in Figure 2.
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genovars, belonging to biovar trachoma, were identified: genovar E was the most frequently found 
infecting seven samples (33.3%), followed by genovar G (19%, four samples), by genovar D and F 
(14.3%, three samples each), H (9.5%, two samples), Ia and Ja (4.8%, one sample each). 
2.6. HPV/C. Trachomatis Co-Infections 
Among the 537 undocumented migrant women, 17 (3.2%; 95% CI: 1.9–5) were HPV/Ct 
co-infected. There were no specific socio-demographic or sexual/reproductive health characteristics, 
or features of the infecting pathogen, associated with co-infection. 
2.7. Diagnostic and Therapeutic Follow-Up 
All of the 155 HPV- and/or Ct-infected women were contacted by phone in order to inform 
them of their STI status and to make a medical appointment. Overall, 28 (18.1%) women did not 
answer the phone despite repeated attempts, 60 (38.7%) did not attend the medical appointment for 
work, logistical, and/or personal reasons, and 67 (43.2%) agreed to undergo a gynaecological 
examination and to have suitable treatment. The outcome of the Pap test carried out on 58 HPV 
DNA positive women was: negative cytology in 77.6% (45/58) and atypical squamous cells of 
undetermined significance (ASC-us) in 32.4% (13/58). Six women (6/13; 46.2%) with ASC-us were 
infected with HPV types belonging to the HR-clade (HPV-16, -26, -51, -56, -66 and -82, respectively) 
and 7 (53.8%) were infected with LR HPV types. Nine Ct infected women received specific antibiotic 
treatment. 
The flowchart with the design of the study and the main results is reported in Figure 2. 
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2.8. N. gonorrhoeae and T. vaginalis Detection
T. vaginalis and N. gonorrhoeae DNA was detected in the anonymous residual aliquots from the
537 samples collected in the pivotal study.
The overall percentage of Tv DNA positivity was 4.8% (95% CI: 3.3–7.0; 26/537), with the highest
infection rate (11.6%; 95% CI: 5.1–24.5; 5/43) among women from the Eastern Mediterranean region,
and the lowest among those from Latin America (2.4%; 95% CI: 1.1–5.2; 26/245) (p = not significant).
The proportion of women infected with Tv was 7.9% (95% CI: 4.7–13.0; 13/165) and 5.6% (95% CI:
1.5–18.1; 2/36) in Europe and in the Western Pacific, respectively. None of the 14 women from Southeast
Asia were infected with Tv.
The median age of infected women was 39.5 years (IQR: 29.5–46.5) and the prevalence increased
according to age up to 54 years (3.6%, 4.3%, 6.1%, 6.8% among women aged <25, 25–34, 35–44, 45–54
years, respectively). Seven women Tv DNA positive (1.3%; 95% CI: 0.6–2.7; 7/537) were also HPV
and/or Ct co-infected: 3 women had a Tv/HPV co-infection, 3 a Tv/Ct co-infection and one woman
had a triple infection Tv/HPV/Ct. There were no women infected with Ng.
3. Discussion
Most of the United Nations member states have ratified treaties recognizing the right to equal and
equitable access to health care for all persons, notwithstanding their legal standing within a government
system [8,9]. In Europe, much attention has been paid to the health of migrants due to the intensification
of human mobility across continents especially in recent years. However, accurate information
on migrants and their health status are not available in many European countries. In addition,
both existing epidemiological and health data may have been underestimated due to difficulties
in including undocumented migrants [17]. Health care access for undocumented migrants varies
considerably between countries, and they are generally less likely to gain access to it than legal
residents [8,9]. Not having access to appropriate health care can lead to severe outcomes that could
otherwise be managed or treated. Among the migrant population, women are the most vulnerable to
health problems and well-being. In this context, reproductive and sexual health and STIs in particular
are the main public health issues affecting migrant women.
In some European countries, such as Austria, Denmark, Finland, Ireland, Luxembourg, and
Sweden, undocumented migrants are only legally entitled to receive emergency health care, even if
they pay for it, and do not have access to family planning or to regular sexual and reproductive health
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check-ups and screening for STIs [7–10]. Furthermore, in other countries, restrictive policies ban or
impose restrictions on the over-the-counter sale of emergency contraception. For example, in Hungary,
emergency contraception requires a prescription, which is often inaccessible for undocumented migrant
women [7–10].
In Italy, although health care is available to all migrants under Italian law, including those who
lack legal documents, no national prevention strategy is directed to female migrants, therefore they do
not have access to screening programs.
The aim of this study was to outline and evaluate STI screening and to gain knowledge on the
spread of HPV and C. trachomatis infections among undocumented migrant women living in Milan,
who attend the NAGA Centre.
A large number of women participated in the study with an acceptance rate of 70.9%.
This percentage of participation in molecular screening (HPV DNA testing) is much higher than
that observed in previous offers of conventional cytological screening (Pap test) at the NAGA Centre
(estimated acceptance rate of approximately 4%, unshown data).
Patient counseling and self-collected urine samples proved to be preferable for these women and
contributed to the successful outcome of the study. During counseling women received information
on the diagnosis, prevention, screening and treatment of sexually transmitted infections and diseases.
This strategy has helped women to overcome their fears and prejudices related to sexual health and
they were therefore more willing to undergo free screening for HPV and C. trachomatis infections.
Urine sampling, a methodology already tested and validated by us [18,19], thus avoiding gynecological
examination as well as socio-cultural and religious implications, proved to be non-invasive, easy and
quick, and therefore a good alternative to conventional cervical brush for Pap screening. Furthermore,
the offer of a “real time” STI screening may have been the tipping point for participation.
This was not the case for the next step of diagnosis or treatment after screening. In fact, a high
loss to follow-up was observed, since only 43.2% (a low, yet significant proportion) of women positive
for HPV and/or C. trachomatis DNA agreed to undergo further investigation. This was probably due
to the long interval between the actual screening and the follow-up appointment at the medical centre,
to work commitments or change of residence. LILT Health care is a voluntary medical centre with
a limited availability of appointments, which was the main cause of the long period between sample
collection and examination. As recommended by WHO, the screen-and-treat approach is probably the
only effective preventive strategy for these women at high risk and who are hard to reach [20].
The results from this study have provided baseline data regarding the epidemiology of HPV and C.
trachomatis infections in undocumented migrant women in Milan. The overall HPV and C. trachomatis
prevalence were 24.2% and 7.8%, respectively, and peaks were observed in younger women, aged <25
years (32.5% and 13.2%, respectively). Nearly 70% of HPV positive women were infected by types
known to be at high oncogenic risk; the most detected type was HPV-56 (2.0%), followed by HPV-16
and HPV-52 (1.4% each). These HR-HPV types are known to be the most common in women with
normal cytology worldwide [21]. The prevalent genovar among Ct positive women was genovar E
(33.3%), known to have a biological advantage over the other genovars thanks to its ability to escape
the immune response and to have specific virulence factors, able to facilitate the transmission and
infectious processes [22].
The study population was enrolled among women who freely and randomly had access to the
NAGA Centre during the study period three days per week. It is therefore not representative of the
geographical area of origin, especially for the small number of women from some areas compared to
those from Latin American and Eastern Europe, but it reflects the migratory movement across a large
urban area of Lombardy, which is the region with highest percentage of immigrants in Italy.
The prevalence of HPV and C. trachomatis infections detected in this cohort of irregular immigrants
are not comparable to the prevalence data reported for these two STIs in both the countries of origin
and the host country.
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Regarding HPV infection, a meta-analysis [16] that included 194 studies on approximately one
million women with normal cytological findings worldwide showed the highest HPV infection rates for
women in Sub-Saharan Africa (24.0%), Eastern Europe (21.4%), and Latin America (16.1%). As observed
in our study, there is a peak in the age-specific HPV distribution for young women (<25 years) [21].
The percentage of undocumented migrant women infected with HPV was higher than that
reported for the Italian female population with normal cytology (HPV DNA prevalence: 15.8%) [23],
but lower than the prevalence reported in other studies on migrant women in Italy (42–47.8%) [12,13].
However it is important to note that the women included in these studies came from two geographical
areas at high prevalence of HPV infection (Africa and Eastern Europe), or had a history of prostitution.
The discrepancies are probably due to various socio-demographic characteristics and risk factors.
The prevalence of C. trachomatis infection observed in this cohort of undocumented migrant
women was slightly higher than that reported for Italian women (7.8% vs. 5.2%) [19]. However,
this prevalence is equal to that observed in another study conducted on 233 Eastern European and
Western African immigrant women in Southern Italy (7.7%) [24].
Lastly, the availability of residual DNA aliquots from urine samples collected for the main
study enabled us to investigate the spread of the two other common curable STIs, T. vaginalis and
N. gonorrhoeae infections, in the same population. An overall prevalence of 4.8% was observed for Tv
infection, while no women among the undocumented migrants in Milan were infected by Ng. These
are the first data obtained in Italy for this high-risk cohort and are comparable to the data reported in
women of the general population worldwide (Tv prevalence: 4.0–6.4%; Ng prevalence: 0.6–1.0%) [25].
As regards to the migrant population, data on the prevalence of T. vaginalis are not available.
The European prevalence data for N. gonorrhoeae infection are similar to that observed in the native
population, but active surveillance should be continued due to the increase of this infection among
migrant women in recent years (2000–2010) [25]. In addition, both infections are a major public health
problem since they can cause acute inflammatory disease, premature rupture of membranes and
premature birth, and increase the risk of contracting HIV [25].
Our results show an overall high prevalence of STIs in undocumented migrant women.
The epidemiological profile varies according to geographical origin, since women from Latin America
showed the highest rate of HPV infection while women from the Eastern Mediterranean area had the
highest Ct and Tv infection rates.
4. Materials and Methods
4.1. Study Design
The study was conducted in accordance with the Declaration of Helsinki, and the protocol was
reviewed and approved by the Ethics Committee of the University of Milan, Italy, in April 2012.
The main study was carried out from June 2012 to December 2013 at the NAGA Centre in Milan
(Italy), which is a voluntary association that provides medical and legal assistance to undocumented
migrants, Rom and Sinti [15]. All undocumented female migrants who attended the NAGA Centre
were invited to take part in the study by the multilingual mediators, regardless of the reason (medical
or otherwise) for their visit to the Centre. Informed consent for participating in the study and for
storing residual samples anonymously (by blinding all information except age and geographical
origin) in a bio-bank for future analyses was obtained from all participants. Inclusion criteria of this
study were: the ability to provide informed consent and communicate in Italian or English, Spanish
or French, as suggested by the expert staff employed at the NAGA Centre; aged between 18 and
65 years; absence of a legal residence permit. After having given informed consent, the participants
completed a self-administered questionnaire consisting of 10 multiple-choice questions regarding
their socio-demographic profile (age, marital status, origin, education, migration time) and sexual
and reproductive health behaviour (use of contraceptive methods, age at first intercourse, number of
sexual partners, number of pregnancies, past or current STDs). The questionnaires were available in
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four languages (Italian, English, Spanish, and French). Researchers from the University of Milan and
multilingual NAGA mediators were available on site every Monday, Wednesday and Friday mornings
to help understand and fill in the questionnaire and for a private counseling on health education,
diagnosis and prevention of STIs.
The women were then enrolled in the research study and asked for a urine sample for carrying out
molecular analyses for STIs (HPV DNA and Ct DNA detection). The urine sample was selected, as it is
non-invasive and easy to collect, thus potentially more attractive to women since medical examination
is not required, as well as for socio-cultural and religious implications. All women found to be positive
for HPV and/or Ct infections were informed by the investigator directly or by phone call and then
examined by a gynecologist at the Lega Italiana per la Lotta contro i Tumori (LILT) Healthcare Centre
in Milan [26] for further investigation or treatment, specifically a Pap test and/or antibiotic treatment,
in the case of HPV or Ct infection, respectively. This is a voluntary medical organization.
4.2. Sample Collection and DNA Extraction
First void urine samples were obtained from each woman in sterile containers, which were stored
at room temperature (RT) and processed within 6–8 h after collection at the Virology Laboratory of
the Department of Biomedical Science for Health, University of Milan. In order to obtain the cellular
component, at least 15 mL of each sample was pre-treated by means of two different successive steps
of centrifugation and washing, as previously described [18] and stored at −20 ◦C until nucleic acid
extraction. DNA was extracted from 500 µL of concentrated urine samples using the NucliSENS®
easyMAG™ automate (bioMérieux bv, Lyon, France) method following the standard protocol with
off-board lysis. The elution volume was 100 µL. The concentration and purity of the DNA extracted
were evaluated using a spectrophotometer (NanoDrop™ 2000 c, Thermo Fisher Scientific, Inc.,
Wilmington, Germany). We determined the quality of the DNA by detecting a 268 base pair (bp)
fragment of the housekeeping beta-globin gene using an in house polymerase chain reaction (PCR)
assay [27]. The DNA extracted was used for HPV and Ct molecular analyses and the residue was
stored at −20 ◦C for further analyses.
4.3. Molecular Assays
4.3.1. HPV Detection and Genotyping
The PCR-based method utilized in this study was previously validated using paired cervical
and urine samples, showing high sensitivity and specificity for the detection and genotyping of HPV
DNA in urine samples [18]. Briefly, HPV DNA was detected through PCR amplification of a 450 bp
segment of the Open Reading Frame (ORF) L1 using the degenerate primer pair ELSI-f and ELSI-r.
Every PCR reaction included positive (HPV-16 positive cells, Caski) and negative (water) controls.
All amplified fragments were then subjected to viral type analysis by means of the RFLP method
that is capable of identifying all HPV types (HR and LR types) of the alpha genus according to the
latest IARC classification system (HR-clade, group 1: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59;
group 2A: HPV-68; group 2B: HPV-26, 30, 34, 53, 66, 67, 69, 70, 73, 82, 85; LR types: HPV-6, 11, 28, 32,
40, 42, 43, 44, 54, 55, 57, 61, 62, 71, 72, 74, 81, 83, 84, 86, 87, 89) [16].
4.3.2. C. trachomatis Detection and Genotyping
Ct DNA was detected through nested PCR amplification of a 150 bp fragment of the cryptic
plasmid [28]. Each PCR run included positive (Ct positive urine sample) and negative (water) controls.
In order to identify Ct genovar, all positive samples underwent sequencing following emi-nested PCR
amplification of a 993 bp fragment of the ompA gene [28]. The sequences obtained were compared with
reference strains present in the GenBank database (BLASTn) [29] to establish the genovar.
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4.3.3. N. gonorrhea and T. vaginalis Detection
Once the main study was concluded, the residual DNA was used in an in house duplex RealTime
PCR (Applied Biosystems 7300 Real Time PCR System, Thermo Fisher Scientific, Inc., Wilmington,
Germany) in order to detect the presence of Ng and Tv infections. The target for Ng DNA was
a fragment of 102 bp of the porA pseudogene [30] and the target for Tv DNA was a fragment of 67 bp
of a repeated sequence [31]. Two µL of sample DNA was added to 23 µL in the reaction solution
for amplification with the following thermal cycling conditions: 50 ◦C for 2 min, 95 ◦C for 10 min,
followed by 40 cycles at 95 ◦C for 15 s and at 60 ◦C for 1 min. Every PCR reaction included positive
(Ng DNA and Tv DNA positive urine samples) and negative (water) controls.
4.4. Cytological Diagnosis
All HR-HPV and/or LR-HPV positive women were referred to cytology with the aim of
implementing and motivating a counseling and prevention strategy for the control of STIs.
Pap smears collected from these women were evaluated according to the 2001 Bethesda
System [32] at the LILT Healthcare Centre [26].
4.5. Statistical Analysis
Data were expressed as a median (IQR) and percentages (95% CI) as appropriate. Comparisons
between groups were performed using the chi-square test or Mid-p exact test. A p-value < 0.05 was
considered statistically significant (two-tail test). All statistical analyses were performed with OpenEpi
software, version 3.01 [33].
5. Conclusions
This study emphasizes the importance of developing and implementing public health policies to
improve the health of migrant women, focusing on the respect and the rights of migrants regardless of
their immigration status. To this regard, more appropriate health services that adequately address all
aspects of women's health, especially sexual and reproductive health issues, are required.
To our knowledge, this is the first Italian study focused on STI screening among undocumented
migrant women. The high participation rate underlines the importance of providing urine-based STI
screening at associations and/or organizations dealing with migrants.
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